Showing results (71-80 of 123) with videos related to
Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|May 3, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphomaSharmila Raghunandan, Melinda Pauly, William G Blum, et al.Eclinicalmedicine|November 13, 2023
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patternsValentin Barsan, Yimei Li, Snehit Prabhu, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 DecadesDeepak Kilari, Anita D'Souza, Raphael Fraser, et al.Journal for Immunotherapy of Cancer|August 6, 2021
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemiaJohn E Levine, Stephan A Grupp, Michael A Pulsipher, et al.Transplantation and Cellular Therapy|March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHDMuna Qayed, Urvi Kapoor, Scott Gillespie, et al.Blood|September 12, 2022
Effective treatment of low-risk acute GVHD with itacitinib monotherapyAaron Etra, Alexandra Capellini, Amin Alousi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2026
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALLStephan A Grupp, Shannon L Maude, Susana Rives, et al.Transplantation and Cellular Therapy|December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk GroupNikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.Transplantation and Cellular Therapy|September 2, 2021
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host DiseaseMakda Getachew Zewde, George Morales, Isha Gandhi, et al.Pageof 13